The author(s) received no specific funding for this work.
The recent outbreak of the COVID-19 pandemic has caused a re-evaluation of the effectiveness of convalescent plasma therapy (CPT). This review was carried out to assess the usefulness of CPT in critically ill COVID-19 patients based on the published data to date. To the best of our knowledge, this is the second review of the usefulness of CPT in COVID-19 patients. PubMed, Google Scholar, MEDLINE, and Embase databases were searched for relevant reports up to June 21, 2020. Records of published data were analyzed according to eligibility criteria. Five different studies on CPT for critically ill COVID-19 patients were included in this review. The significant findings from these records are: (a) CPT may help to reduce mortality in the critically ill patients (b) administration of CPT increased antibody titers and reduced the level of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) RNA to below the detection limit (c) transfusion of convalescent plasma (CP) caused clinical symptoms to subside. Based on the currently available data, CPT in COVID-19 patients seems effective and safe and reduces mortality. There is an urgent need to perform well-designed, multicenter clinical trials to establish the efficacy of CPT in COVID-19 patients.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Arif Khan, Muhammad and Ullah, Ikram
"Convalescent Plasma Therapy in Coronavirus Disease 2019 (COVID-19) Patients: A Brief Review,"
The University of Louisville Journal of Respiratory Infections: Vol. 4
, Article 47.
Available at: https://ir.library.louisville.edu/jri/vol4/iss1/47